Logo of plosonePLoS OneView this ArticleSubmit to PLoSGet E-mail AlertsContact UsPublic Library of Science (PLoS)
PLoS ONE. 2008; 3(7): e2705.
Published online 2008 Jul 16. doi:  10.1371/journal.pone.0002705
PMCID: PMC2442191

Identification of a Regulatory T Cell Specific Cell Surface Molecule that Mediates Suppressive Signals and Induces Foxp3 Expression

Patricia Bozza, Editor


Regulatory T (Treg) cells control immune activation and maintain tolerance. How Tregs mediate their suppressive function is unclear. Here we identified a cell surface molecule, called GARP, (or LRRC32), which within T cells is specifically expressed in Tregs activated through the T cell receptor (TCR). Ectopic expression of GARP in human naïve T (TN) cells inhibited their proliferation and cytokine secretion upon TCR activation. Remarkably, GARP over-expression in TN cells induced expression of Treg master transcription factor Foxp3 and endowed them with a partial suppressive function. The extracellular but not the cytoplasmic region of GARP, was necessary for these functions. Silencing Foxp3 in human Treg cells reduced expression of GARP and attenuated their suppressive function. However, GARP function was not affected when Foxp3 was downregulated in GARP-overexpressing cells, while silencing GARP in Foxp3-overexpressing cells reduced their suppressive activity. These findings reveal a novel cell surface molecule-mediated regulatory mechanism, with implications for modulating aberrant immune responses.


Regulatory T cells (Tregs) were recently identified as a specialized subset of T cells that suppress auto-reactive cells to maintain immunological tolerance and inhibit autoimmunity [1]. Tregs have also been shown to control excessive or chronic immune activation after infections with various pathogens [2]. Naturally occurring Tregs are thought to be generated in the thymus, express high levels of CD25 and the transcription factor forkhead box protein P3 (Foxp3), and constitute about 5–10% of periphery total CD4+ T cells in mice [1]. Human and murine Tregs share similar characteristics, such as hypo-responsiveness to T cell receptor (TCR) activation and mediation of their suppressive activity through cell-contact-dependent mechanisms [1]. Foxp3 is critical in Treg development and function. Mice that are deficient in Foxp3 develop severe autoimmune diseases, and mutations of human Foxp3 gene result in immunodysregulation, polyendocrinopathy, enteropathy, X linked syndrome (IPEX), which also is characterized by severe autoimmunity [1], [2].

Although the characteristics and function of Tregs have been extensively studied, mechanisms of how Tregs mediate their suppressive activity are still unclear. Various mechanisms have been proposed, such as cytokine deprivation-induced apoptosis [3], secretion of inhibitory cytokines [4], [5], manipulation of antigen presenting cells (APCs)[6], and recruitment of mast cells [7]. Several molecules have also been proposed to be important in Treg generation, development or function, such as glucocorticoid-induced TNF receptor (GITR)[8], indoleamine 2,3-dioxygenase (IDO)[9], Heme oxygenase-1 (HO-1)[10], lymphocyte activation gene-3 (LAG-3)[11]. How these diverse sets of molecules regulate Treg cell differentiation and suppressive function remain unresolved.

In this report, we identified a Treg cell specific cell surface molecule called GARP or LRRC32. Ectopic expression of GARP in primary human T cells remarkably induced Foxp3 expression and endowed them with partial Treg phenotype, including impairment of proliferative capacity and acquisition of a suppressive activity. Structure-function analysis of GARP revealed that the extracellular domain, but not the cytoplasmic region, was important for its function, suggesting an interaction of GARP with other signaling receptor(s). Thus, determining the role of this novel molecule in Treg mediated suppression could be important in understanding tolerance mechanisms and exploiting its function for regulating immune responses.

Results and Discussion

Identification of a cell surface molecule expressed on activated Treg cells

In order to identify novel molecules that could be involved in human Treg development and function, we first isolated human T cell subsets as previously described [12]. The purified CD4+ T cells from healthy donors, were divided into four subsets based on CD45RO and CD25 staining: 1) Tregs (CD45RO+CD25hi) 2) Memory T (TM) cells (CD45RO+CD25) 3) Naïve T (TN) cells (CD45ROCD25) and 4) Naïve subset of Treg (TNreg) cells (CD45ROCD25hi)[12][15] as shown in Fig. 1A. The fourth group of human T cell subset, TNreg cells, which was recently characterized, displays an intermediate suppressive capacity ex vivo but can be expanded in vitro to develop into fully mature Tregs [12][15]. All four groups of purified T cell subsets were then stimulated through the T cell receptor (TCR) overnight and RNA was extracted for DNA gene chip analysis to identify Treg specific genes. The DNA microarray analysis led to identification of a cell surface molecule that was expressed more than 100 fold in both TNreg and Tregs as compared to TN or TM cells (Fig. 1B). This 662 amino acid (aa) encoding gene, originally called GARP or LRRC32, was found to be expressed at high levels in placenta, lung and kidney [16], [17].

Figure 1
GARP is specifically expressed in activated Treg cells.

To confirm the high expression level of GARP in activated Tregs, we performed quantitative real time RT-PCR (qPCR) analysis of GARP gene expression in all T cell subsets stimulated through the TCR. Consistent with the microarray data, qPCR also showed that the expression levels of GARP in both TNregs and Tregs were more than 100 fold higher as compared to TN cells and about 10 fold higher than TM cells (Fig. 1C).

To determine the kinetics of GARP expression in different T cell subsets, qPCR analysis for GARP expression was performed in TN, TM, TNreg or Treg cells either at a resting state or at different time points post-activation. We found that GARP is rapidly upregulated after TCR stimulation in both TNregs and Tregs (Fig. 1D). Interestingly, high level of GARP persisted for at least 5 days on Tregs, but declined in TNregs within 2 days. This could be because TNregs are not fully mature and have to undergo a differentiation program to sustain GARP expression [12]. However, post in vitro expansion, TNreg cells acquire complete Treg characteristics both phenotypically and functionally [12]. Indeed, in vitro expanded TNregs (hereafter referred as Tregs) also upregulated GARP expression post TCR activation and exhibited kinetics of GARP expression that were similar to Tregs directly isolated from peripheral blood (Fig. 1E and data not shown). Furthermore, ectopic expression of Foxp3 in TN cells, which can program them into Tregs [18] also upregulated GARP mRNA expression (Fig. 1F and data not shown). Taken together these findings suggest that GARP expression is specifically induced on natural or reprogrammed Tregs upon TCR stimulation, and might be involved in maintenance of Treg characteristics or Treg-mediated suppressive activity.

Overexpression of GARP endows TN cells with partial Treg phenotype and function

To explore the role of GARP in Treg development and function, we subcloned human GARP into a HIV-derived vector (HDV) that encodes red fluorescent protein (RFP) as a marker [18]. TN cells were isolated as described above, activated by monocyte-derived dendritic cells (DC) plus superantigen (SEB), and transduced with HDV encoding GARP, Foxp3 or vector only as control. Expression of GARP and Foxp3 in transduced cells was confirmed by qPCR and intracellular staining respectively (data not shown). The transduced cells were expanded in IL-2 containing media for two weeks, and stained for CD25 and CD62L, which are known to be expressed at higher levels on naturally occurring Tregs or on Foxp3-overexpressing T cells [19], [20]. GARP-transduced cells expressed higher levels of CD25 and CD62L than the control vector-transduced cells, but the expression was lower compared to the Foxp3-transduced cells (Fig. 2A). Remarkably, GARP-transduced cells expressed higher level of Foxp3 compared to the cells transduced with the control vector after re-activation with DCs pulsed with SEB (Fig. 2A).

Figure 2
Ectopic expression of GARP endows TN cells with partial Treg phenotype and function.

To determine whether GARP-expressing T cells display functional properties of Tregs, transduced cells were sorted on the basis of RFP expression and stimulated through DCs pulsed with SEB at suboptimal concentrations. Cytokine production in the activation culture was assessed. T cells ectopically expressing GARP secreted lower levels of IL-2 and IFNγ compared to control vector-transduced T cells (Fig. 2B). To assess the proliferative capacity of GARP-expressing cells, transduced cells were labeled with Carboxyfluorescein succinimidyl ester (CFSE) and stimulated through TCR. GARP-expressing cells also displayed decreased proliferative capacity as compared to the T cells expressing vector only, when stimulated with DC and suboptimal SEB (Fig. 2C). Furthermore, GARP-expressing cells displayed some suppressive activity against TN targets, although this was not as potent as Foxp3-transduced cells (Fig. 2D). Taken together, our data indicate that T cells ectopically expressing GARP acquire a partial phenotypic and functional profile of Tregs.

GARP function requires the extracellular region but not the cytoplasmic portion

The GARP gene encodes a cell surface protein with a signal peptide (SP) for cell surface translocation [21], an extracellular region that is composed of 20 leucine-rich repeats (LRRs), a transmembrane domain (TM) and a short cytoplasmic region of 15 aa [17], [22]. LRR domains in other proteins are involved in a variety of functions, principally through protein-protein interaction [23]. Because GARP has a very short cytoplasmic region, we hypothesized that only the extracellular LRRs and the SP are required for its function. Accordingly, we prepared three different mutants: 1) Deletion of the cytoplasmic tail (ΔC), 2) Deletion of all LRRs in the N-terminus (ΔN), and 3) Deletion of the SP at the N-terminus (ΔSP). These mutants are shown schematically in Fig. 3A. All mutants were sequence confirmed and subcloned into the HDV, and lentiviral vectors were generated to transduce primary TN cells. Phenotypic analysis revealed that TN cells expressing the ΔC mutant showed similar upregulation of CD25, CD62L and Foxp3 expression compared to the WT GARP, whereas T cells expressing the ΔN or ΔSP GARP mutants had lost this activity (Fig. 3B and 3C).

Figure 3
Phenotypic and functional analysis of T cells ectopically expressing GARP mutants.

Next, we compared proliferative capacity, cytokine production and suppressive activity of the mutants to the WT GARP. Similar to the surface phenotype, TN cells transduced with the ΔC mutant exhibited impaired proliferative capacity, reduced cytokine production, and enhanced suppressive capacity comparable to WT GARP-expressing cells (Fig. 3D–F). However, the ΔN and ΔSP mutant-expressing cells did not display any of the inhibitory functions of GARP-expressing cells (Fig. 3D–F). Together, these data indicate that both the SP and the LRRs in the extracellular portion of GARP, but not the cytoplasmic domain, are crucial to its function.

Does GARP mediate its inhibitory function through expression of Foxp3?

We have shown that GARP was upregulated in freshly isolated TNreg, Treg and Foxp3-expressing cells as well as in vitro expanded Tregs (Fig. 1). These findings suggest that GARP is a potential downstream effector molecule in Tregs. However, T cells ectopically expressing GARP also upregulate Foxp3 expression in a sizeable portion of these cells (Fig. 2A). Therefore, it is possible that functional and phenotypic changes observed upon GARP overexpression could be indirectly due to induction of Foxp3, which then induces other effector molecules. To address this possibility we performed an experiment to silence Foxp3 expression in GARP-transduced cells using shRNA against Foxp3. Cells were then expanded for two weeks and efficient knockdown of Foxp3 expression was confirmed (Fig. 4A). As shown in Fig. 4B, silencing Foxp3 in GARP-expressing cells did not alter their suppressive ability, while downregulation of Foxp3 in Tregs resulted in significant attenuation of their suppressive capability [12], which was reduced to similar levels as GARP-expressing cells (Fig. 4B). Moreover, GARP-expressing cells produced reduced levels of cytokines even in the presence of Foxp3 shRNA (Fig. 4C), which was similar to control shRNA expressing cells (data not shown). In addition, silencing Foxp3 expression in Treg cells reduced induction of GARP upon TCR activation (Fig. 4D), which correlated with partial loss of suppressive activity in these cells (Fig. 4B). These findings suggest that induction of GARP in Tregs is dependent on Foxp3 expression, while its inhibitory action on T cell activation is independent of sustained expression of Foxp3.

Figure 4
GARP functions as a downstream effector molecule of Foxp3 expression.

Silencing GARP in Foxp3-induced Treg cells attenuate their suppressive activity

Induction of GARP expression requires the expression of Foxp3 while it can mediate its function independent of Foxp3 expression. Based on these findings we hypothesize that GARP is an effector molecule of suppression downstream of Foxp3 expression. To test this hypothesis further, we silenced GARP expression through shRNA in Foxp3-induced Tregs. We designed two different shRNAs against GARP, which reduced the expression of GARP between 60 to 80% in Foxp3-induced Tregs (data not shown). We found that expression of GARP-shRNA in Foxp3-induced Tregs attenuated their suppressive activity as compared to the control shRNA expressing cells (Fig. 5). This important result supports our hypothesis that a sizeable part of suppressive activity mediated by Foxp3 is through the induction of GARP in Treg cells.

Figure 5
Silencing GARP in Foxp3-induced Tregs attenuate their suppressive activity.


Naturally occurring Tregs are crucial to the establishment of immunological tolerance. Despite intense research, the mechanisms by which Tregs mediate their suppressive effect are not completely understood. Here we identified a molecule, called GARP, which mediates part of the Treg suppressive activity. Ectopic expression of GARP in human TN cells resulted in a partial Treg phenotype, as determined by increased Foxp3, CD25 and CD62L expression, decreased cytokine production (IFNγ and IL-2), impaired proliferative capacity and display of suppressive activity. Silencing GARP in Foxp3-induced Tregs reduced their suppressive function. These data suggest a pivotal role for GARP in controlling aberrant or unwanted T cell activation.

GARP is highly conserved across species, suggesting that it mediates an important function [24]. The mouse and human GARP amino acid sequences share 82% identity. The similarity rises to 87% if conservative amino acid changes are allowed, which argues the possibility for cross-reaction between mouse GARP with human GARP binding partners. Indeed, similar to the human counterpart, murine GARP was also upregulated only in mature murine Tregs upon activation (Figure S1). Further, murine GARP-expressing human T cells exhibited a very similar phenotype as those expressing human GARP (Figure S1 C–F). We conclude that both murine and human GARP are able to interact with the human GARP binding partners. Future genetic manipulation in mice to determine the role of GARP in vivo will be invaluable in understanding the role of this molecule in function and development of Treg cells.

GARP gene, originally called GARP, contains two exons. The first exon encodes the signal peptide and nine amino acid residues, and the second one contains 20 repeats of the LRR motif, the transmembrane domain and a short cytoplasmic domain [17], [24]. We found that deletion of LRRs in GARP results in complete loss of its function, while mutant lacking the short cytoplasmic domain behaved similarly to the WT GARP. The LRRs are generally 20–29 residues long, with the consensus sequence LxxLxLxxN/CxL. Proteins with LRR constitute a large superfamily involved in diverse functions, such as adenylate cyclase in yeast, the proteoglycans decorin and biglycan in human, and disease resistance genes in plants [23]. GARP, as an LRR containing molecule (LRRC32), shows similarity to glycoprotein V, which is one of the components forming the GPIb-IX-V complex on platelet surface famous for the interaction with von Willebrand factor complex to mediate the adhesion of platelets to injured vascular surfaces [25]. It was recently shown that GARP is expressed on the cell surface of platelets using a polyclonal antibody raised against its extracellular portion [22]. In addition, we generated GFP-tagged versions of WT and ΔSP mutant of GARP and based on image analysis of cells expressing a GFP, confirmed WT but not ΔSP, appears to be localized to cell surface region (Figure S2). This expression profile of GARP suggests that LRRs at the extracellular region could mediate its function, possibly through interaction with another cell surface molecule(s). We also ruled out that GARP-mediated suppression is mediated by a soluble factor since neither separating GARP-expressing cells via transwells nor adding supernatants from these cells to target cells showed any suppressive function (data not shown). Our finding that the cytoplasmic region was dispensable also strongly argues the possibility that GARP itself is not likely to be delivering intracellular signals but conceivably may interact with a receptor molecule expressed by target T cells, which deliver inhibitory signals. Alternatively, GARP may be part of a signaling surface complex similar to glycoprotein V [25].

We found that GARP was induced in T cells ectopically expressing Foxp3 and reduced in expression when Foxp3 was silenced in natural Tregs. These findings suggest that Foxp3 is a regulator of GARP expression. It remains to be determined whether Foxp3 directly activates GARP transcription or indirectly through other transcription factors. It will also be interesting to determine whether in IPEX patients or scurfy mice, which have defective expression or mutations in Foxp3, GARP expression is also reduced. Although Foxp3 appears to be required for GARP expression in T cells, silencing Foxp3 in cells forced to express GARP does not reduce their suppressive function. Furthermore, we showed that silencing of GARP in Foxp3-induced Tregs diminished their suppressive function. Together these data imply that GARP is an effector molecule downstream of Foxp3 that can directly display inhibitory signaling once it is expressed.

Peripheral tolerance to self-antigens is an important secondary mechanism that prevents autoimmune reactions [26]. In addition, Tregs have also been proposed to play a role in pregnancy by allowing continuous release of placental antigens into the maternal circulation, thus permitting tolerance towards the semiallogeneic fetus until birth [9], [27]. Previous studies postulated cellular pathways affected by Treg action including production of inhibitory cytokines, enhanced IDO expression and HO-1 induction [9]. Interestingly, GARP was found to be highly expressed in placenta in both mouse and human [17], [24]. Expression of GARP in placenta might be essential in creating a “tolerant” privileged microenvironment to avoid rejection of the fetus, and this privilege could even be independent of Tregs, although it remains to be determined whether GARP expression on non-T cells can also inhibit T cell activation.

In summary, GARP is highly specific to activated Treg cells, and has the ability to mediate partial Treg characteristics, importantly including their suppressive function. Identification of this Treg cell specific molecule may have implications in understanding regulation of unwanted immune responses and sustaining tolerance by Treg cells. The discovery of GARP as an immune suppressive molecule in primary human T cells may also be relevant for exploiting the function of this molecule to modulate immune responses during autoimmunity, transplantation or persistent immune activation caused by chronic infections such as HIV. Conversely, blocking GARP signals can amplify immune responses to antigens in the context of vaccine development or boost the immune response to infections and tumors.

Materials and Methods

Cell purification and culture

TN, TM, TNreg and Treg cells, were purified and cultured as described before [12], [18]. Monocyte-derived dendritic cells (DCs) were generated from CD14+ cells from healthy donors as previously described [18]. The superantigen, staphylococcal enterotoxin B (SEB) was purchased from Sigma (St. Louis, MO). The cytokines used were from R&D Systems (Minneapolis, MN).

Microarray gene analysis

106 T cells from each subset (TN, TM, TNreg and Treg) were activated by plate-bound anti-CD3 antibody (OKT-3; American Type Culture Collection, Manassas, VA) and soluble anti-CD28 antibody (1 μg/ml, BD Biosciences, San Diego, CA) for 16 hours. RNA was extracted from flash frozen cells and subjected to Agilent whole Genome 4×44K arrays at a commercial service (Genus Biosystems, Northbrook, IL).


Total RNA was isolated and cDNA was synthesized as described before [18]. The cDNA was then used to perform qPCR using a Stratagene Mx3005P (La Jolla, CA) or Applied Biosystems 7300 apparatus (Foster City, CA). TaqMan primer and probe mixes were purchased from Applied Biosystems, and their IDs are as follows: β−actin (used as a reference gene): Hs99999903_ml; GARP: Hs00194136_m1.

Cloning of GARP gene and construction of mutants

Full length human GARP cDNA (LRRC32) was purchased from Origene (Rockville, MD) and amplified using the primers:

  • 5′forward: cacctctagagccatgagaccccagat;
  • 3′reverse: cccgggcttctttaggctttata.

To construct C-terminus truncated mutant (ΔC), the following primers were used:

  • 5′forward: cacctctagagccatgagaccccagat;

The amplified DNA was then cloned into pENTR/D-TOPO® vector system (Invitrogen). The N-terminus mutant (ΔN) was cloned through PCR from WT GARP TOPO construct using the following primer sets

  • 5′forward: gAGTactcagctgctgcggc;

The PCR product was ligated to construct the ΔN mutant. WT GARP and the mutants were then subcloned into a HIV-derived HDV expressing RFP (Clontech Laboratories, Mountain View, CA) as marker gene as described [18]. To construct signal peptide deleted mutant (ΔSP), the following primers were used:


To amplify murine GARP from cDNA library, the following primers were used:


The PCR product of murine GARP and ΔSP mutant was then subcloned into the HDV. All constructs were sequence confirmed. Lentiviruses expressing GARP or other genes used here were generated as previously described [18].

Silencing of Foxp3 and GARP expression in primary T cells

Foxp3 or GARP shRNA-expressing lentiviral vectors with GFP as a marker was generated as previously described [12]. Two different Foxp3 shRNA sequence were tested and both showed efficient knock down of Foxp3 [12]. Both were used in experiments presented here with representatives of both (Fig. 4D) or one shRNA (sh2, Fig. 4A–C). The shRNA oligos against GARP were : sh1: GGAATTCCCTCACCTGCATCT; sh2: GGAGAACAAACTGCTCCATTT.

FACS analysis

Cells were stained, analyzed as described before [12]. The following antibodies were used for staining: CD45RO, CD25 (both from BD Biosciences), CD62L (eBioscience, San Diego, CA). Foxp3 expression was performed with anti-Foxp3 antibody (clone 259D; Biolegend, San Diego, CA) through intracellular staining as described before [12].

Cell proliferation, suppression and cytokine assays

Cells were labeled with CFSE (Molecular Probes, Eugene, OR) as previously described [18] and activated by DC and SEB at different concentrations. Supernatant from the culture were collected 16–40 hours later. Suppression assays were set up as previously described [12]. Cytokine production was measured using cytometric bead array (CBA; BD Biosciences) and analyzed by FlowJo (Tree Star, Ashland, OR). Data represent the mean±SEM of experiments from at least three different donors. Proliferation of the cells was assessed by monitoring expression CFSE on day 4 or day 5 post-activation.

Detection of GARP by fluorescence microscope

WT GARP was PCR amplified with following primers:

  • 5′forward: cacctctagagccatgagaccccagat;

ΔSP mutant GARP was PCRed using primers:


The PCR products were ligated in pcDNA3.1/CT-GFP-TOPO® vector system (Invitrogen). Both constructs were transfected into 293T cells by lipofectamine 2000 (Invitrogen) following the manufacture's instructions. pcDNA3.1 GFP was used as control. 24 hours post transfection, cells were washed with cold PBS, fixed at 4°C in 4% paraformaldehyde for 10 min, washed one more time with PBS and mounted on glass coverslips in Aqua Poly/Mount (Polysciences, Inc, Warrigton, PA). Samples were visualized by Zeiss, Axiover 200 fluorescence microscope (Bernried, Germany), recorded by QImaging Retiga EX digital camera (Minneapolis, MN) and analyzed by Openlab 3.1.7 (Improvision, Lexington, MA). Nuclei were stained with Hoechst 33342 (Invitrogen).

Detection of mouse GARP in murine T cell subsets

CD4+CD25 and CD4+CD25+ T cells were purified from spleen of C57BL/6 mice by FACS. Sorted cells were stimulated with anti-CD3 and anti-CD28 antibodies (2 μg/ml each) for 24 hours. CD4CD8 (double negative, DN), CD4+CD8+ (double positive, DP), CD4 single positive (SP) and CD8 SP cells were purified from thymus of C57BL/6 mice by FACS. mRNA were purified and subjected to cDNA synthesis. Primers used for detection of mouse GARP are:


Primers for detection of mouse G3PDH (glyceraldehyde-3-phosphate dehydrogenase) are described previously [28].

Statistical Analysis

The significance was determined using One-Sample Student's t-test or One-way ANOVA.

Supporting Information

Figure S1

Murine GARP is functionally similar to human counterpart. A) Murine GARP (mGARP) expression in mouse T cell subsets. mGARP expression in different T cell subsets and developing stages in mice as determined by semi-quantitative PCR. DN, double negative; DP, double positive; SP, single positive. G3PDH was used as loading control. One representative experiment of three is shown. (B) mGARP-transduced human TN cells displayed high levels of CD25 and CD62L expression and (C) Foxp3 expression post-activation. Cells were transduced and prepared as described in Fig. 2. M, Geometric mean. (D) Cytokine profiles of mGARP-transduced cells. Data are shown by first normalizing the control to be 100% and represent the mean±SEM of experiments from at least three different donors. Range of control production (pg/ml): IL-2, 300–1000; IFNγ, 3000–10000. *, P<0.05, n = 3; experimental versus control. (E) mGARP-transduced cells exhibited impaired proliferative capacity and (F) intermediate suppressive activity. Data are representative experiments from at least three different donors.

(0.14 MB TIF)

Figure S2

Localization of WT GARP but not ΔSP mutant to cell surface. Control GFP, WT GARP-GFP and ΔSP mutant GARP-GFP fusion protein expression in transfected 293T cells. Green, GFP; blue, Dapi. Shown are two representative merged images for WT and ΔSP mutant expressing cells.

(0.17 MB PDF)


We thank Dr. Vineet KewalRamani, Dr. Chris Arendt, Dr, Alka Khaitan, Frances Mercer and Dr. Simge Akbulut for critical reading and advice on the manuscript. We also thank Shella Saint Fleur and Adriana Arita for their technical assistance.


Competing Interests: The authors have declared that no competing interests exist.

Funding: This work was supported by NIH grant R01 AI065303 to Derya Unutmaz and NIH Grant R01 AI059315 to Hodaka Fujii.


1. Sakaguchi S. Naturally arising Foxp3-expressing CD25+CD4+ regulatory T cells in immunological tolerance to self and non-self. Nat Immunol. 2005;6:345–352. [PubMed]
2. Belkaid Y. Regulatory T cells and infection: a dangerous necessity. Nat Rev Immunol. 2007;7:875–888. [PubMed]
3. Pandiyan P, Zheng L, Ishihara S, Reed J, Lenardo MJ. CD4(+)CD25(+)Foxp3(+) regulatory T cells induce cytokine deprivation-mediated apoptosis of effector CD4(+) T cells 2007 [PubMed]
4. Yamagiwa S, Gray JD, Hashimoto S, Horwitz DA. A role for TGF-beta in the generation and expansion of CD4+CD25+ regulatory T cells from human peripheral blood. J Immunol. 2001;166:7282–7289. [PubMed]
5. Collison LW, Workman CJ, Kuo TT, Boyd K, Wang Y, et al. The inhibitory cytokine IL-35 contributes to regulatory T-cell function. Nature. 2007;450:566–569. [PubMed]
6. Mahnke K, Ring S, Johnson TS, Schallenberg S, Schonfeld K, et al. Induction of immunosuppressive functions of dendritic cells in vivo by CD4(+)CD25(+) regulatory T cells: Role of B7-H3 expression and antigen presentation. Eur J Immunol 2007 [PubMed]
7. Lu LF, Lind EF, Gondek DC, Bennett KA, Gleeson MW, et al. Mast cells are essential intermediaries in regulatory T-cell tolerance. Nature. 2006;442:997–1002. [PubMed]
8. Ji HB, Liao G, Faubion WA, Abadia-Molina AC, Cozzo C, et al. Cutting edge: the natural ligand for glucocorticoid-induced TNF receptor-related protein abrogates regulatory T cell suppression. J Immunol. 2004;172:5823–5827. [PubMed]
9. Zenclussen AC, Schumacher A, Zenclussen ML, Wafula P, Volk HD. Immunology of pregnancy: cellular mechanisms allowing fetal survival within the maternal uterus. Expert Rev Mol Med. 2007;9:1–14. [PubMed]
10. Xia ZW, Zhong WW, Xu LQ, Sun JL, Shen QX, et al. Heme oxygenase-1-mediated CD4+CD25high regulatory T cells suppress allergic airway inflammation. J Immunol. 2006;177:5936–5945. [PubMed]
11. Huang CT, Workman CJ, Flies D, Pan X, Marson AL, et al. Role of LAG-3 in regulatory T cells. Immunity. 2004;21:503–513. [PubMed]
12. Antons AK, Wang R, Oswald-Richter K, Tseng M, Arendt CW, et al. Naive Precursors of Human Regulatory T Cells Require FoxP3 for Suppression and Are Susceptible to HIV Infection. J Immunol. 2008;180:764–773. [PubMed]
13. Seddiki N, Santner-Nanan B, Tangye SG, Alexander SI, Solomon M, et al. Persistence of naive CD45RA+ regulatory T cells in adult life. Blood. 2006;107:2830–2838. [PubMed]
14. Hoffmann P, Eder R, Boeld TJ, Doser K, Piseshka B, et al. Only the CD45RA+ subpopulation of CD4+CD25high T cells gives rise to homogeneous regulatory T-cell lines upon in vitro expansion. Blood. 2006;108:4260–4267. [PubMed]
15. Valmori D, Merlo A, Souleimanian NE, Hesdorffer CS, Ayyoub M. A peripheral circulating compartment of natural naive CD4 Tregs. J Clin Invest. 2005;115:1953–1962. [PMC free article] [PubMed]
16. Ollendorff V, Szepetowski P, Mattei MG, Gaudray P, Birnbaum D. New gene in the homologous human 11q13-q14 and mouse 7F chromosomal regions. Mamm Genome. 1992;2:195–200. [PubMed]
17. Ollendorff V, Noguchi T, deLapeyriere O, Birnbaum D. The GARP gene encodes a new member of the family of leucine-rich repeat-containing proteins. Cell Growth Differ. 1994;5:213–219. [PubMed]
18. Oswald-Richter K, Grill SM, Shariat N, Leelawong M, Sundrud MS, et al. HIV infection of naturally occurring and genetically reprogrammed human regulatory T-cells. PLoS Biol. 2004;2:E198. [PMC free article] [PubMed]
19. Sakaguchi S, Sakaguchi N, Asano M, Itoh M, Toda M. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol. 1995;155:1151–1164. [PubMed]
20. Salomon B, Lenschow DJ, Rhee L, Ashourian N, Singh B, et al. B7/CD28 costimulation is essential for the homeostasis of the CD4+CD25+ immunoregulatory T cells that control autoimmune diabetes. Immunity. 2000;12:431–440. [PubMed]
21. Pugsley AP. Translocation of proteins with signal sequences across membranes. Curr Opin Cell Biol. 1990;2:609–616. [PubMed]
22. Macaulay IC, Tijssen MR, Thijssen-Timmer DC, Gusnanto A, Steward M, et al. Comparative gene expression profiling of in vitro differentiated megakaryocytes and erythroblasts identifies novel activatory and inhibitory platelet membrane proteins. Blood. 2007;109:3260–3269. [PubMed]
23. Kobe B, Kajava AV. The leucine-rich repeat as a protein recognition motif. Curr Opin Struct Biol. 2001;11:725–732. [PubMed]
24. Roubin R, Pizette S, Ollendorff V, Planche J, Birnbaum D, et al. Structure and developmental expression of mouse Garp, a gene encoding a new leucine-rich repeat-containing protein. Int J Dev Biol. 1996;40:545–555. [PubMed]
25. Canobbio I, Balduini C, Torti M. Signalling through the platelet glycoprotein Ib-V-IX complex. Cell Signal. 2004;16:1329–1344. [PubMed]
26. Romagnani S. Regulation of the T cell response. Clin Exp Allergy. 2006;36:1357–1366. [PubMed]
27. Zenclussen AC, Gerlof K, Zenclussen ML, Ritschel S, Zambon Bertoja A, et al. Regulatory T cells induce a privileged tolerant microenvironment at the fetal-maternal interface. Eur J Immunol. 2006;36:82–94. [PubMed]
28. Hoshino A, Fujii H. Redundant promoter elements mediate IL-3-induced expression of a novel cytokine-inducible gene, cyclon. FEBS Lett. 2007;581:975–980. [PMC free article] [PubMed]

Articles from PLoS ONE are provided here courtesy of Public Library of Science
PubReader format: click here to try


Save items

Related citations in PubMed

See reviews...See all...

Cited by other articles in PMC

  • A Large-Scale Genetic Analysis Reveals a Strong Contribution of the HLA Class II Region to Giant Cell Arteritis Susceptibility[American Journal of Human Genetics. 2015]
    Carmona FD, Mackie SL, Martín JE, Taylor JC, Vaglio A, Eyre S, Bossini-Castillo L, Castañeda S, Cid MC, Hernández-Rodríguez J, Prieto-González S, Solans R, Ramentol-Sintas M, González-Escribano MF, Ortiz-Fernández L, Morado IC, Narváez J, Miranda-Filloy JA, Spanish GCA GroupMartínez-BerriochoaAgustínAUnzurrunzagaAinhoaAHidalgo-CondeAnaAMadroñero-VueltaAna B.ABFernández-NebroAntonioAOrdóñez-CañizaresM. CarmenMCEscalanteBegoñaBMarí-AlfonsoBegoñaBSopeñaBernardoBMagroCésarCRayaEnriqueEGrauElenaERománJosé A.JAde MiguelEugenioELópez-LongoF. JavierFJMartínezLinaLGómez-VaqueroCarmenCFernández-GutiérrezBenjamínBRodríguez-RodríguezLuisLDíaz-LópezJ. BernardinoJBCaminal-MonteroLuisLMartínez-ZapicoAleidaAMonfortJordiJTíoLauraLSánchez-MartínJulioJAlegre-SanchoJuan J.JJSáez-CometLuisLPérez-ConesaMercedesMCorbera-BellaltaMarcMGarcía-VillanuevaM. JesúsMJFernández-ContrerasM. EncarnaciónMESanchez-PernauteOlgaOBlancoRicardoROrtego-CentenoNorbertoNRíos-FernándezRaquelRCallejasJosé L.JLFanlo-MateoPatriciaPMartínez-TaboadaVíctor M.VM, Beretta L, Lunardi C, Cimmino MA, Gianfreda D, Santilli D, Ramirez GA, Soriano A, Muratore F, Pazzola G, Addimanda O, Wijmenga C, Witte T, Schirmer JH, Moosig F, Schönau V, Franke A, Palm Ø, Molberg Ø, Diamantopoulos AP, Carette S, Cuthbertson D, Forbess LJ, Hoffman GS, Khalidi NA, Koening CL, Langford CA, McAlear CA, Moreland L, Monach PA, Pagnoux C, Seo P, Spiera R, Sreih AG, Warrington KJ, Ytterberg SR, Gregersen PK, Pease CT, Gough A, Green M, Hordon L, Jarrett S, Watts R, Levy S, Patel Y, Kamath S, Dasgupta B, Worthington J, Koeleman BP, de Bakker PI, Barrett JH, Salvarani C, Merkel PA, González-Gay MA, Morgan AW, Martín J. American Journal of Human Genetics. 2015 Apr 2; 96(4)565-580
  • The Environment of Regulatory T Cell Biology: Cytokines, Metabolites, and the Microbiome[Frontiers in Immunology. ]
    Hoeppli RE, Wu D, Cook L, Levings MK. Frontiers in Immunology. 661
  • GP96 is a GARP chaperone and controls regulatory T cell functions[The Journal of Clinical Investigation. 2015...]
    Zhang Y, Wu BX, Metelli A, Thaxton JE, Hong F, Rachidi S, Ansa-Addo E, Sun S, Vasu C, Yang Y, Liu B, Li Z. The Journal of Clinical Investigation. 2015 Feb 2; 125(2)859-869
  • Mesenchymal Stromal Cells Express GARP/LRRC32 on Their Surface: Effects on Their Biology and Immunomodulatory Capacity[Stem Cells (Dayton, Ohio). 2015]
    Carrillo-Galvez AB, Cobo M, Cuevas-Ocaña S, Gutiérrez-Guerrero A, Sánchez-Gilabert A, Bongarzone P, García-Pérez A, Muñoz P, Benabdellah K, Toscano MG, Martín F, Anderson P. Stem Cells (Dayton, Ohio). 2015 Jan; 33(1)183-195
  • Discovery in Genetic Skin Disease: The Impact of High Throughput Genetic Technologies[Genes. ]
    Maruthappu T, Scott CA, Kelsell DP. Genes. 5(3)615-634
See all...


  • Compound
    PubChem chemical compound records that cite the current articles. These references are taken from those provided on submitted PubChem chemical substance records. Multiple substance records may contribute to the PubChem compound record.
  • Gene
    Gene records that cite the current articles. Citations in Gene are added manually by NCBI or imported from outside public resources.
  • Gene (nucleotide)
    Gene (nucleotide)
    Records in Gene identified from shared sequence and PMC links.
  • GEO Profiles
    GEO Profiles
    Gene Expression Omnibus (GEO) Profiles of molecular abundance data. The current articles are references on the Gene record associated with the GEO profile.
  • HomoloGene
    HomoloGene clusters of homologous genes and sequences that cite the current articles. These are references on the Gene and sequence records in the HomoloGene entry.
  • MedGen
    Related information in MedGen
  • Nucleotide
    Primary database (GenBank) nucleotide records reported in the current articles as well as Reference Sequences (RefSeqs) that include the articles as references.
  • Pathways + GO
    Pathways + GO
    Pathways and biological systems (BioSystems) that cite the current articles. Citations are from the BioSystems source databases (KEGG and BioCyc).
  • Protein
    Protein translation features of primary database (GenBank) nucleotide records reported in the current articles as well as Reference Sequences (RefSeqs) that include the articles as references.
  • PubMed
    PubMed citations for these articles
  • Substance
    PubChem chemical substance records that cite the current articles. These references are taken from those provided on submitted PubChem chemical substance records.

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...